Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma.

Yasuyuki MizutaniTadashi IidaEizaburo OhnoTakuya IshikawaFumie KinoshitaYachiyo KuwatsukaMiwa ImaiShinobu ShimizuToshihisa TsurutaAtsushi EnomotoHiroki KawashimaMitsuhiro Fujishiro

Published in: BMC cancer (2022)

Clinicaltrial.gov: NCT05064618 , registered on 1 October 2021. jRCT: jRCT2041210056 , registered on 27 August 2021.

Keyphrases

clinical trial
open label
study protocol
randomized controlled trial
adverse drug
electronic health record